Valsartan Hidrohlorotiazid Mylan 160 mg/1 tableta+ 12,5 mg/1 tableta film tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

valsartan hidrohlorotiazid mylan 160 mg/1 tableta+ 12,5 mg/1 tableta film tableta

mylan d.o.o. - hidrohlorotiazid, валсартан - film tableta - 160 mg/1 tableta+ 12,5 mg/1 tableta - 1 tableta sadrži: 160 mg valsartana i 12,5 mg hidrohlorotiazida

Valsartan Hidrohlorotiazid Mylan 80 mg/1 tableta+ 12,5 mg/1 tableta film tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

valsartan hidrohlorotiazid mylan 80 mg/1 tableta+ 12,5 mg/1 tableta film tableta

mylan d.o.o. - hidrohlorotiazid, валсартан - film tableta - 80 mg/1 tableta+ 12,5 mg/1 tableta - 1 tableta sadrži: 80 mg valsartana i 12,5 mg hidrohlorotiazida

VALSARTAN Mylan 160 mg/1 tableta film tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

valsartan mylan 160 mg/1 tableta film tableta

mylan d.o.o. - валсартан - film tableta - 160 mg/1 tableta - 1 film tableta sadrži: 160 mg valsartana

VALSARTAN Mylan 80 mg/1 tableta film tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

valsartan mylan 80 mg/1 tableta film tableta

mylan d.o.o. - валсартан - film tableta - 80 mg/1 tableta - 1 film tableta sadrži: 80 mg valsartana

Xaluprine (previously Mercaptopurine Nova Laboratories) Europska Unija - hrvatski - EMA (European Medicines Agency)

xaluprine (previously mercaptopurine nova laboratories)

nova laboratories ireland limited - 6-merkaptopurin monohidrat - leukemija, limfoid - antineoplastična sredstva - xaluprin je indiciran za liječenje akutne limfoblastične leukemije (all) u odraslih, adolescenata i djece.

Jayempi Europska Unija - hrvatski - EMA (European Medicines Agency)

jayempi

nova laboratories ireland limited - azathioprine - odbacivanje transplantata - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Atsimutin 25 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

atsimutin 25 mg filmom obložene tablete

pharmaswiss Česká republika s.r.o., jankovcova 1569/2c, prag, Češka - azathioprinum - filmom obložena tableta - 25 mg - urbroj: jedna filmom obložena tableta sadrži 25 mg azatioprina

Atsimutin 50 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

atsimutin 50 mg filmom obložene tablete

pharmaswiss Česká republika s.r.o., jankovcova 1569/2c, prag, Češka - azathioprinum - filmom obložena tableta - 50 mg - urbroj: jedna filmom obložena tableta sadrži 50 mg azatioprina

Ig Vena 50 g/l otopina za infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

ig vena 50 g/l otopina za infuziju

kedrion s.p.a., ai conti, castelvecchio pascoli, barga (lucca), italija - imunoglobulin normalni, ljudski, intravenski - otopina za infuziju - 50 g/l - urbroj: 1 ml otopine sadrži: imunoglobulin normalni, ljudski, intravenski 50 mg (čistoće od najmanje 95% igg)

Imuran 50 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

imuran 50 mg filmom obložene tablete

aspen pharma trading limited, 3016 lake drive, citywest business campus, dublin, irska - azatioprin - filmom obložena tableta - 50 mg - urbroj: jedna tableta sadrži 50 mg azatioprina